Fennec Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fennec Pharmaceuticals Inc.
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.
The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m.
Fennec Pharmaceuticals says that its new formulation of sodium thiosulfate for preventing cisplatin-induced hearing loss in children targets a critical unmet medical need.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Adherex Technologies Inc.
- Cadherin Biomedical, Inc.
- Fennec Pharmaceuticals (EU) Limited
- Oxiquant, Inc.